Screener
Haemonetics HAE R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Cost of goods sold | 136,577 | 129,150 |
| Gross profit | 202,803 | 192,244 |
| Operating expenses: | ||
| Research and development | 16,200 | 16,261 |
| Selling, general and administrative | 118,941 | 110,719 |
| Amortization of acquired intangible assets | 10,204 | 11,392 |
| Total operating expenses | 145,345 | 138,372 |
| Operating income | 57,458 | 53,872 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's R&D?
- Haemonetics (HAE) reported R&D of $16.2M in Q2 2026.
- How has Haemonetics's R&D changed year-over-year?
- Haemonetics's R&D decreased by 0.4% year-over-year, from $16.26M to $16.2M.
- What is the long-term trend for Haemonetics's R&D?
- Over 4 years (2022 to 2026), Haemonetics's R&D has grown at a 6.3% compound annual growth rate (CAGR), from $46.8M to $59.77M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Haemonetics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude